Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature

Jennifer K. Bender, Vincent Cattoir, Kristin Hegstad, Ewa Sadowy, Teresa M. Coque, Henrik Westh, Anette M. Hammerum, Kirsten Schaffer, Karen Burns, Stephen Murchan, Carla Novais, Ana R. Freitas, Luísa Peixe, Maria Del Grosso, Annalisa Pantosti, Guido Werner

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Vancomycin-resistant enterococci (VRE) are important nosocomial pathogens. Invasive VRE infections are difficult to treat since common therapeutic options including ampicillin and glycopeptides often fail. In vitro, most VRE remain susceptible to last-resort antibiotics such as linezolid, tigecycline and daptomycin. However, neither tigecycline nor linezolid act in a bactericidal manner, and daptomycin has proven activity only at high dosages licensed for treating enterococcal endocarditis. Despite these pharmacological and therapeutic limitations, reports on resistance to these last-resort drugs in VRE, and enterococci in general, have increased in recent years. In this review, we briefly recapitulate the current knowledge on the mode of action as well as the known and novel mechanisms of resistance and describe surveillance data on resistance to linezolid, tigecycline and daptomycin in enterococci. In addition, we also suggest a common nomenclature for designating enterococci and VRE with resistances to these important last-resort antibiotics.

Original languageEnglish
Pages (from-to)25-39
Number of pages15
JournalDrug Resistance Updates
Volume40
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Linezolid
Daptomycin
Enterococcus
Terminology
Anti-Bacterial Agents
Glycopeptides
Ampicillin
Endocarditis
Vancomycin-Resistant Enterococci
tigecycline
Pharmacology

Keywords

  • Daptomycin
  • Linezolid
  • Tigecycline
  • vanA
  • vanB
  • VRE

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Cancer Research
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe : Towards a common nomenclature. / Bender, Jennifer K.; Cattoir, Vincent; Hegstad, Kristin; Sadowy, Ewa; Coque, Teresa M.; Westh, Henrik; Hammerum, Anette M.; Schaffer, Kirsten; Burns, Karen; Murchan, Stephen; Novais, Carla; Freitas, Ana R.; Peixe, Luísa; Del Grosso, Maria; Pantosti, Annalisa; Werner, Guido.

In: Drug Resistance Updates, Vol. 40, 01.09.2018, p. 25-39.

Research output: Contribution to journalArticle

Bender, JK, Cattoir, V, Hegstad, K, Sadowy, E, Coque, TM, Westh, H, Hammerum, AM, Schaffer, K, Burns, K, Murchan, S, Novais, C, Freitas, AR, Peixe, L, Del Grosso, M, Pantosti, A & Werner, G 2018, 'Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature', Drug Resistance Updates, vol. 40, pp. 25-39. https://doi.org/10.1016/j.drup.2018.10.002
Bender, Jennifer K. ; Cattoir, Vincent ; Hegstad, Kristin ; Sadowy, Ewa ; Coque, Teresa M. ; Westh, Henrik ; Hammerum, Anette M. ; Schaffer, Kirsten ; Burns, Karen ; Murchan, Stephen ; Novais, Carla ; Freitas, Ana R. ; Peixe, Luísa ; Del Grosso, Maria ; Pantosti, Annalisa ; Werner, Guido. / Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe : Towards a common nomenclature. In: Drug Resistance Updates. 2018 ; Vol. 40. pp. 25-39.
@article{7344e20605c14c779d8066064b340265,
title = "Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature",
abstract = "Vancomycin-resistant enterococci (VRE) are important nosocomial pathogens. Invasive VRE infections are difficult to treat since common therapeutic options including ampicillin and glycopeptides often fail. In vitro, most VRE remain susceptible to last-resort antibiotics such as linezolid, tigecycline and daptomycin. However, neither tigecycline nor linezolid act in a bactericidal manner, and daptomycin has proven activity only at high dosages licensed for treating enterococcal endocarditis. Despite these pharmacological and therapeutic limitations, reports on resistance to these last-resort drugs in VRE, and enterococci in general, have increased in recent years. In this review, we briefly recapitulate the current knowledge on the mode of action as well as the known and novel mechanisms of resistance and describe surveillance data on resistance to linezolid, tigecycline and daptomycin in enterococci. In addition, we also suggest a common nomenclature for designating enterococci and VRE with resistances to these important last-resort antibiotics.",
keywords = "Daptomycin, Linezolid, Tigecycline, vanA, vanB, VRE",
author = "Bender, {Jennifer K.} and Vincent Cattoir and Kristin Hegstad and Ewa Sadowy and Coque, {Teresa M.} and Henrik Westh and Hammerum, {Anette M.} and Kirsten Schaffer and Karen Burns and Stephen Murchan and Carla Novais and Freitas, {Ana R.} and Lu{\'i}sa Peixe and {Del Grosso}, Maria and Annalisa Pantosti and Guido Werner",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.drup.2018.10.002",
language = "English",
volume = "40",
pages = "25--39",
journal = "Drug Resistance Updates",
issn = "1368-7646",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe

T2 - Towards a common nomenclature

AU - Bender, Jennifer K.

AU - Cattoir, Vincent

AU - Hegstad, Kristin

AU - Sadowy, Ewa

AU - Coque, Teresa M.

AU - Westh, Henrik

AU - Hammerum, Anette M.

AU - Schaffer, Kirsten

AU - Burns, Karen

AU - Murchan, Stephen

AU - Novais, Carla

AU - Freitas, Ana R.

AU - Peixe, Luísa

AU - Del Grosso, Maria

AU - Pantosti, Annalisa

AU - Werner, Guido

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Vancomycin-resistant enterococci (VRE) are important nosocomial pathogens. Invasive VRE infections are difficult to treat since common therapeutic options including ampicillin and glycopeptides often fail. In vitro, most VRE remain susceptible to last-resort antibiotics such as linezolid, tigecycline and daptomycin. However, neither tigecycline nor linezolid act in a bactericidal manner, and daptomycin has proven activity only at high dosages licensed for treating enterococcal endocarditis. Despite these pharmacological and therapeutic limitations, reports on resistance to these last-resort drugs in VRE, and enterococci in general, have increased in recent years. In this review, we briefly recapitulate the current knowledge on the mode of action as well as the known and novel mechanisms of resistance and describe surveillance data on resistance to linezolid, tigecycline and daptomycin in enterococci. In addition, we also suggest a common nomenclature for designating enterococci and VRE with resistances to these important last-resort antibiotics.

AB - Vancomycin-resistant enterococci (VRE) are important nosocomial pathogens. Invasive VRE infections are difficult to treat since common therapeutic options including ampicillin and glycopeptides often fail. In vitro, most VRE remain susceptible to last-resort antibiotics such as linezolid, tigecycline and daptomycin. However, neither tigecycline nor linezolid act in a bactericidal manner, and daptomycin has proven activity only at high dosages licensed for treating enterococcal endocarditis. Despite these pharmacological and therapeutic limitations, reports on resistance to these last-resort drugs in VRE, and enterococci in general, have increased in recent years. In this review, we briefly recapitulate the current knowledge on the mode of action as well as the known and novel mechanisms of resistance and describe surveillance data on resistance to linezolid, tigecycline and daptomycin in enterococci. In addition, we also suggest a common nomenclature for designating enterococci and VRE with resistances to these important last-resort antibiotics.

KW - Daptomycin

KW - Linezolid

KW - Tigecycline

KW - vanA

KW - vanB

KW - VRE

UR - http://www.scopus.com/inward/record.url?scp=85056446191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056446191&partnerID=8YFLogxK

U2 - 10.1016/j.drup.2018.10.002

DO - 10.1016/j.drup.2018.10.002

M3 - Article

C2 - 30447411

AN - SCOPUS:85056446191

VL - 40

SP - 25

EP - 39

JO - Drug Resistance Updates

JF - Drug Resistance Updates

SN - 1368-7646

ER -